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Inhibitor of apoptosis proteins are required
for effective fusion of autophagosomes
with lysosomes
Sylwia Gradzka1,2, Oliver S. Thomas1,2, Oliver Kretz3,4,5, Aladin Haimovici1,2, Lazaros. Vasilikos6, Wendy Wei-Lynn Wong6,
Georg Häcker1,2 and Ian E. Gentle 1,2
Abstract
Inhibitor of Apoptosis Proteins act as E3 ubiquitin ligases to regulate NF-κB signalling from multiple pattern
recognition receptors including NOD2, as well as TNF Receptor Superfamily members. Loss of XIAP in humans causes
X-linked Lymphoproliferative disease type 2 (XLP-2) and is often associated with Crohn’s disease. Crohn’s disease is also
caused by mutations in the gene encoding NOD2 but the mechanisms behind Crohn’s disease development in XIAP
and NOD2 deﬁcient-patients are still unknown. Numerous other mutations causing Crohn’s Disease occur in genes
controlling various aspects of autophagy, suggesting a strong involvement of autophagy in preventing Crohn’s
disease. Here we show that the IAP proteins cIAP2 and XIAP are required for efﬁcient fusion of lysosomes with
autophagosomes. IAP inhibition or loss of both cIAP2 and XIAP resulted in a strong blockage in autophagic ﬂux and
mitophagy, suggesting that XIAP deﬁciency may also drive Crohn’s Disease due to defects in autophagy.
Introduction
IAPs are ubiquitin ligases that regulate the activity of
TNF Super Family Receptors (TNFSFR), TLRs and NOD
receptors. By attaching ubiquitin onto substrates such as
RIPK1 they regulate the activation of NF-κB and deter-
mine the outcome of signals from these receptors. Their
inhibition results in skewing of signals towards death and
also production of an inﬂammatory cytokine response1–4.
The three best characterised and functionally related IAP
members are cIAP1, cIAP2 and XIAP. cIAP1 and cIAP2
act together in complex with TRAF2 and TRAF35–7. Loss
of cIAP1 leads to defective NF-κB signals from partner
receptors such as TNFR1 and additional activation of
non-canonical NF-κB1. Less is known about XIAP and its
regulation other than it is required for NF-κB signals from
NOD2 receptor due to its ubiquitylation activity towards
RIPK28.
Genetic loss of cIAP1, cIAP2 and XIAP results in severe
systemic inﬂammation characterised by massive increases
in many cytokines including TNF and IL-1β 2. IAP
antagonist drugs are also able to trigger activation of
NLRP3 inﬂammasomes in LPS primed macrophages3. In
both cases there appears to be an important role for XIAP,
in addition to cIAP1 and cIAP2, in suppressing this
inﬂammatory cascade suggesting some redundancy in the
function of IAPs.
Humans with mutations in XIAP often develop Crohn’s
disease (CD) but may also suffer from X-linked lympho-
proliferative disease 2 (XLP-2)9–12. NOD2 is also com-
monly mutated in CD patients13–16. Although mutations
in XIAP affect the activation of NOD2, the molecular
mechanisms behind CD in these mutations are still not
clear. Another gene commonly mutated in CD is the
autophagy gene ATG16L117. NOD2 and Atg16L1 are also
functionally linked with NOD2 being required for
recruiting ATG16L1 to internalised bacteria such as
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Salmonella during xenophagy, the targeted autophagy of
invading bacteria18. CD associated mutations in NOD2
and Atg16L1 were also shown to block autophagy
induction by NOD2 and reduce the xenophagy of invad-
ing Salmonella19. Defects in Atg16L1 or NOD2 also
increased the replication of adherent-invasive Escherichia
coli (AIEC) in macrophages, resulting in enhanced cyto-
kine production. Conversely, induction of autophagy in
NOD2−/− macrophages reduced survival of AIEC and
cytokine production20. Together these data suggest that
autophagy is a key pathway linking NOD2 and ATG16L1
in the development of Crohn’s disease and hint that XIAP
may also have some role in autophagy regulation.
Autophagy is a highly conserved pathway for recycling
cellular components in times of nutrient limitation.
Autophagosomes are formed around cellular components
such as bulk cytoplasm (macroautophagy), but also spe-
ciﬁc targets including mitochondria (mitophagy), invasive
bacteria (xenophagy) and aggregated proteins (aggre-
phagy). In each case phagophores, fuse to make
Fig. 1 IAP inhibition triggers autophagosome accumulation. a Wild type MEFs expressing mcherry-GFP-LC3b were treated with the indicated
doses of LCL161or thapsigargin for 6 h. DNA was stained using Hoechst and live Cells were imaged to visualise mCherry, GFP and Hoechst. The
number of GFP+ puncta and mCherry+ puncta were then counted per cell and the ratio of GFP+ /mCherry+ puncta calculated. Graphs represent
the mean and error bars show SEM of at least 3 experiments. b IAP antagonism does not block lysosomal acidiﬁcation. Wild type MEFs were treated
with either LCL161 (5 μM), thapsigargin (3 μM) or concanamycin A (2 nM) for 6 h. Cells were stained with lysotracker red and visualised by microscopy
or lysotracker intensity measured via ﬂow cytometry. Graphs represent the mean of the geometric mean ﬂuorescence intensity measured by ﬂow
cytometry and error bars show SEM of at least 3 independent experiments. P values were calculated using T-test in Prism software
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autophagosomes that fuse with lysosomes, releasing their
contents to be degraded and recycled (reviewed in refs.21–
23). Autophagy is also linked to many other functions in
animals, including regulation of the immune system at
various levels such as xenophagy, MHCII presentation,
limiting cytokine production in response to infection, and
in protein folding diseases such as Alzheimer’s disease
(AD) (reviewed in refs.24–27).
We here show that both cIAP2 and XIAP promote
autophagosome–lysosome fusion and that their loss or
inhibition results in accumulation of autophagosomes and
lysosomes and defects in mitophagy and xenophagy.
Results
IAP antagonism causes accumulation of autophagosomes
To determine if there was any effect of IAP antagonists
on autophagy, Mouse Embryonic Fibroblasts (MEFs) were
infected with pBabe-mCherry-EGFP-LC3b. GFP ﬂuores-
cence is sensitive to pH and decreases in the acidic
environment of autolysosomes while mCherry retains its
ﬂuorescence. Due to this property of GFP, this reporter
can be used to assess the rate at which autophagosomes
are synthesised and degraded by lysosomes.
Since there is continuous fusion with lysosomes at
steady state, there are more single mCherry+ puncta in
cells expressing GFP-mCherry-LC3b than GFP+
mCherry+ puncta, and the ratio of GFP+ and mCherry
+ puncta can be used to illustrate this spontaneous
fusion. The Cells were treated with the IAP antagonist
LCL-16128. Upon treatment of MEFs with LCL161, there
was a clear accumulation of GFP+ puncta at doses as low
as 500 nM (Fig. 1a). A slight accumulation of mCherry+
puncta could also be detected at this dose but the ratio of
GFP/mCherry increased substantially. Treatment with 5
μM LCL161 resulted in more mCherry+GFP+ puncta
and a ratio of GFP+ /mCherry+ close to one (Fig. 1a).
Similar results were seen with an unrelated IAP antago-
nist, birinapant that also lead to signiﬁcant blockage of
fusion events, but only at doses of 50 µM or above
(Supplementary Fig. 1). Thapsigargin, an irreversible
inhibitor of the SERCA calcium pumps of the ER, has
been shown to speciﬁcally inhibit the fusion of autophagic
vesicles with lysosomes, resulting in build up of GFP+
mCherry+ puncta29. As a positive control, MEFs were
also treated with thapsigargin, which triggered a build up
of GFP+mCherry+ puncta as expected. The ratio of
GFP+ /mCherry+ puncta was close to one, reﬂecting its
function in blocking fusion of autophagosomes with
lysosomes and similar to the results seen for treatment
with IAP antagonists (Fig. 1a). IAP-antagonism therefore
causes a build-up of GFP+mCherry+ LC3 positive
vesicles in MEFs.
This build-up of GFP+mCherry+ LC3 positive vesi-
cles could be a result of either a deﬁciency in turnover of
autophagosomes or an increase in activation of autop-
hagy. Defects in autophagosome turnover occur by a
number of mechanisms. One possibility is a failure to
acidify the autolysosome, resulting in defective lysosomal
enzyme function. Such an effect is seen upon the addition
of drugs like concanamycin A, an inhibitor of this later
stage in autophagy that blocks the activity of ATPase
proton pumps in the lysosome, preventing acidiﬁcation
and blocking degradation of lysosomal cargo.
To rule out an effect of IAP antagonists on lysosomal
acidiﬁcation, MEFs were treated with IAP antagonists or
concanamycin A to block acidiﬁcation, or thapsigargin to
block autophagosomal fusion with lysosomes. MEFs were
then stained with Lysotracker Red, which only ﬂuoresces
when lysosomes are acidiﬁed. Cells were analysed by
microscopy and ﬂow cytometry (Fig. 1b). IAP antagonist
treatment did not reduce lysotracker ﬂuorescence
whereas Concanamycin A did (Fig. 1b). Both thapsigargin
treatment and higher doses of LCL161 enhanced lyso-
tracker staining (Fig. 1b), suggesting a possible accumu-
lation of lysosomes in addition to autophagosomes. IAP
antagonists do not therefore affect the acidiﬁcation of
lysosomes, but do lead to a build-up of mCherry+ /GFP
+ positive puncta in a fashion similar to thapsigargin.
Electron Microscopy (EM) was performed on LCL161
treated MEFs, as well as thapsigargin treated MEFs and
untreated controls. LCL161 treated cells showed a clear
increase in vesicular structures containing cellular debris
suggesting they are autophagosomes (Fig. 2). The same
was seen for thapsigargin treatment. Of note is that
electron dense lysosomes cluster in regions adjacent to
autophagosomes, but do not appear to be fused with the
autophagosomes (Fig. 2). Immunoﬂuoresence was also
perfomed on wt MEFs treated with LCL161 or birinapant
to conﬁrm that endogenous LC3 also shows a similar
accumulation after IAP antagonism (Fig. 3). There is a
striking accumulation of autophagosomes, in the peri-
nuclear region. Surprisingly these autophagosomes appear
to surround lysosomes (LAMP2+ structures) as opposed
to co-localising with them which is similar to the non-
fused, but associated, autophagosomes and lysosomes
seen by EM (Fig. 2) and is indicative of recruitment of
autophagosomes to lysosomes, but failure to fuse. The
same effect was seen with birinapant but to a lesser extent
than with LCL161.
IAP antagonists block autophagic ﬂux
Blocking fusion of autophagosomes with lysosomes
hinders autophagic ﬂux. Autophagic ﬂux can be analysed
by preventing formation of new autophagosomes and
chasing preformed autophagosomes through to their
fusion with lysosomes. Inhibition of PI3K activity blocks
the early stages of autophagosome formation, but allows
existing autophagosomes to continue through autophagic
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Fig. 2 Electron microscopy of IAP antagonist treated cells shows autophagosome and lysosome accumulation. MEFs were treated with
thapsigargin (3 μM) or LCL161 (0.5 μM) for 6 h. Cells were ﬁxed and analysed by EM. a Overview of whole cells showing increased vesicularization in
LCL161 and thapsigargin treated cells. b Magniﬁcation of LCL161 (I–II) or thapsigargin (IV–VI) treated cells showing I+IV. Accumulation of lysosomes,
II+V. Lysosome associated but not fused to autophagosome, III+VI. Autophagosomes with cellular debris inside
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ﬂux, and be degraded by lysosomes. In cells expressing
mCherry-GFP-LC3b this leads to the loss in the GFP
signal29.
To analyse if IAP antagonists can block fusion with
lysosomes, cells were ﬁrst starved in HBSS and treated
with different combinations of PI3K inhibitor and/or IAP
antagonist or thapsigargin. When cells were ﬁrst starved
by incubation in HBSS for 2 h, there was, as expected, a
substantial increase in the number of GFP+ puncta, while
the number of mCherry+ puncta remained grossly
similar (Fig. 4a). Addition of LY294002 (LY), a PI3K
inhibitor known to block autophagy, for 1 h caused the
number of GFP+ puncta to return to control levels,
showing that the existing autophagosomes fused with
lysosomes and lost their GFP ﬂuorescence. Addition of
LCL161 with LY reversed this GFP+ puncta loss, as did
addition of thapsigargin. Conversely, addition of LY to
cells pre-treated with LCL161 or thapsigargin failed to
reduce the number of autophagosomes which had accu-
mulated (Fig. 4a) conﬁrming that pre-existing autopha-
gosomes did not chase through to fusion with lysosomes.
These data show that LCL and thapsigargin can both
block the turnover of existing autophagosomes that have
been triggered to form by starvation. These experiments
were also performed with 0.5 μM LCL161 with similar
results although reduced in degree (data not shown).
Autophagic ﬂux was further analysed by measuring
induction of LC3-II in response to concanamycin A
treatment. Concanamycin A, as described above, blocks
the last stages of autophagy by blocking acidiﬁcation of
lysosomes. Addition of concanamycin A therefor leads to
increased LC3-II levels when autophagy is induced for
example by starvation, but shows no increase in LC3-II
levels if the late stages of autophagy are blocked, due to
the redundancy in effect. We therefore treated MEFs
expressing mCherry-GFP-LC3 with either HBSS to
induce starvation, or with LCL161. Cells were treated with
concanamycin A and analysed by Western blot for levels
of mCherry-GFP-LC3-II. There was a clear concanamycin
A induced increase in LC3-II in both control and HBSS
treated cells, however concanamycin A failed to increase
LC3-II in LCL161 treated cells (Fig. 4). Similar results
Fig. 3 Endogenous LC3 accumulates around lysosomes. Wild type MEFs were treated with LCL161 (5 µM) or birinapant (50 µM) or DMSO as a
control for 6 h. Cells were ﬁxed and stained with antibodies against LAMP2 (red channel) and LC3 (green channel). Cells were imaged by confocal
microscopy
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Fig. 4 (See legend on next page.)
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were seen using birinapant (data not shown). These
results again argue that IAP antagonism blocks autophagy
autophagosome–lysosome fusion stage.
cIAP2 and XIAP but not cIAP1 regulate autophagic ﬂux
LCL161 and birinapant both target cIAP1 and cIAP2
with higher afﬁnity than XIAP. The increase in severity of
the phenotype in response to higher doses of
LCL161 suggests that XIAP may play a role. To identify
which IAPs regulate autophagy and to conﬁrm that this
phenotype was speciﬁc to IAP antagonism and not an off
target effect of the IAP antagonist drugs, siRNA knock-
down was used to silence expression of cIAP1, cIAP2 or
XIAP. Efﬁcient silencing was achieved for each gene
(Fig. 5a). cIAP2 loss was conﬁrmed using qPCR, cIAP1
and XIAP loss were determined by western blot. Loss of
cIAP2 or XIAP increased GFP+ /mCherry+ ratio closer
to 1, similar to IAP antagonist treatment at lower doses
(0.5 µM) (Fig. 5). Surprisingly however, siRNA against
cIAP1 had no signiﬁcant effect on the GFP+ /mCherry+
ratio suggesting that build-up of GFP+ autophagosomes
due to IAP antagonism is likely a result of cIAP2 and
XIAP antagonism. We were unable to suppress expres-
sion of both cIAP2 and XIAP simultaneously using siRNA
in MEFs; at the concentrations required the transfection
reagents alone induced build-up of autophagosomes,
something that has previously been reported30. However,
given the higher afﬁnity of birinapant and LCL161 for
cIAP1 and cIAP2 over XIAP, the effect seen at low doses
is likely mostly due to cIAP2 inhibition.
To determine if loss of both cIAP2 and XIAP together
could replicate inhibition of autophagosome–lysosome
fusion seen with higher doses of IAP antagonist drugs,
cIAP1ﬂ/ﬂ cIAP2−/− XIAP−/− dermal ﬁbroblasts were
infected with lentivirus expressing mCherry-GFP-LC3,
and the ratio of GFP+ /mCherry+ vesicles quantiﬁed.
Genotyping of the cells conﬁrmed knockout of cIAP2 and
XIAP (Supplementary Fig. 2). The cIAP1ﬂ/ﬂ cIAP2−/−
XIAP−/− cells showed a GFP+ /mCherry+ ratio close to
1 without any treatment (Fig. 5b). Additionally, cIAP1ﬂ/ﬂ
cIAP2−/− XIAP−/− cells have increased endogenous LC3
levels (Fig. 5c). Starvation reduced LC3-II levels in wild
type cells, probably due to a high rate of ﬂux, but this was
less so for cIAP1ﬂ/ﬂ cIAP2−/− XIAP−/− cells, indicating a
reduced rate of ﬂux (Fig. 5c). Immunoﬂuorescence against
Lamp2 and LC3 showed dramatic accumulation of LC3 in
the starved cIAP1ﬂ/ﬂ cIAP2−/− XIAP−/− cells compared
to the wild type (Fig. 5d). At steady state, while there is
some accumulation of autophagosomes, the difference is
not as clear, suggesting adaptation to loss of cIAP2 and
XIAP (Fig. 5d). Loss of both cIAP2 and XIAP together
therefore inhibits autophagosome–lysosome fusion caus-
ing reduced ﬂux through the autophagy pathway
IAP antagonists block turnover of long-lived proteins
Basal autophagic activity is responsible for degradation
of long-lived proteins that are not normally turned over
by proteasomal degradation. To determine if IAP inhibi-
tion could block turnover of long-lived proteins, wild type
and Atg5−/− MEFs were labelled using click-iT chemistry
with L-Azidohomoalanine (AHA). AHA is incorporated
in place of methionine when cells are cultured in
methionine free media. The degradation of long-lived
proteins can then be monitored by labelling with a
ﬂuorophore and monitoring ﬂuorescence by ﬂow
cytometry31.
Starvation in HBSS for three hours resulted in a
decrease in ﬂuorescence indicating a reduction of existing
stained proteins (Fig. 6). The same treatment in ATG5−/−
MEFs showed no signiﬁcant reduction in ﬂuorescence
conﬁrming the reduction observed is speciﬁc to autop-
hagy mediated degradation. Co-incubation of wild type
cells with HBSS and thapsigargin also completely blocked
the decrease in labelled protein, showing that blocking
fusion of autophagosomes and lysosomes also blocks
protein turnover. Co-incubation with HBSS and LCL161
or birinapant also blocked turnover of long-lived proteins
although incompletely, presumably because at these lower
doses XIAP is not targeted and only the loss of cIAP2-
function was observed (Fig. 6).
IAPs do not regulate endocytosis
Autophagosomes use some of the same machinery for
lysosomal fusion as the endocytic trafﬁcking system
including SNAREs, Rab7 and the class C/HOPS tethering
complex29, 32, 33. Blockage of autophagosome–lysosome
(see ﬁgure on previous page)
Fig. 4 IAP antagonism blocks autophagic ﬂux. a MEFs expressing mcherry-gfp-lc3b were treated as shown in the timeline by either starving cells
in HBSS for 1 h or treating with thapsigragin (3 μM) or LCL161 (5 μM) for 5 h. LY294002 (20 μM) was then added for 1 h either alone or, in the HBSS
starved conditions, thapsigargin or LCL161 were also added together with LY294002. Cells were imaged and GFP+ and mCherry+ puncta /cell
counted. Graphs show means error bars show SEM of at least 3 experiments. b MEFs expressing mCherry-GFP-LC3b were either left untreated,
starved in HBSS for 2 h or treated with LCL161 (0.5 μM) for 6 h. In each condition cells were also treated with or without concanamycin A (2 nM) for
the ﬁnal hour. Cells were lysed and levels of mCherry-GFP-LC3B detected by western blot. For each condition the amount of mCherry-GFP-LC3BII was
normalised to actin levels in the non concanamycin A treated sample. The graph shows the mean fold change in mCherry-GFP-LC3BII from at least 3
independent experiments and error bars show SEM. P values were calculated using T-test in Prism software
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fusion may represent a more general defect in endocytic
membrane fusion caused by IAP antagonists. To test this,
we monitored internalisation and degradation of EGFR,
which upon activation is degraded in lysosomes after
endosomal trafﬁcking. There was no change in EGFR
degradation rate in LCL161 treated cells while con-
canamycin A treated cells showed a near complete loss of
degradation (Fig. 7a). Additionally we analysed ﬂuid phase
endocytosis using uptake of ﬂuorescently labelled dextran
and trafﬁcking of labelled endosomes to lysosomes by co-
staining with lysotracker. No difference could be detected
in the amount of dextran-labelled endosomes co-
localising with lysosomes in treated and control cells
(Fig. 7b). This was conﬁrmed by Pearson’s correlation
coefﬁcient analysis, which also clearly showed that the
degree of co-localisation is not altered signiﬁcantly by IAP
Fig. 5 cIAP2 and XIAP regulate autophagosome fusion, but not cIAP1. a MEFs expressing mCherry-GFP-LC3b were transfected with siRNA
against either cIAP1, cIAP2 or XIAP. Cells were analysed with the microscope and the number of mCherry+, and GFP+ puncta/cell were calculated
and the ratio of GFP+ /mCherry+ puncta is indicated. Shown are the means and the error bars represent the SEM of at least three independent
experiments. Westerns show efﬁcient knockdown of cIAP1 and XIAP expression. cIAP2 siRNA efﬁciency was determined by real time PCR as shown in
the graph below the westerns. b Wild type and cIAP2−/− XIAP−/− dermal ﬁbroblasts expressing mCherry-GFP-LC3b were treated analysed on the
microscope and mCherry+, and GFP+ puncta/cell were calculated. The ratio of GFP+/mCherry+ puncta is indicated. c Wild type and cIAP2−/−
XIAP−/− dermal ﬁbroblasts were left in complete media (CM) or starved for 2 h in EBSS. Cells were lysed and proteins analysed by western blot for
XIAP, LC3, and Actin. cIAP2−/− was conﬁrmed by PCR due to lack of effective antibodies for mouse cIAP2 (see supplemental Fig. 2). d
Immunoﬂuoresence showing accumulation of LC3 in starved cIAP2−/− XIAP−/− dermal ﬁbroblasts. Wild type and cIAP2−/− XIAP−/− dermal
ﬁbroblasts were incubated in complete media or starved in EBSS for 2 h, then ﬁxed and stained for LC3 (green channel) and LAMP2 (red channel).
Nuclei are stained blue with Hoechst. Shown in upper panels are overviews. Lower panels show zoomed in regions indicated in the upper panels
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antagonism (Fig. 7b). Together these results clearly show
that IAP antagonism has no effect on the endosomal
pathway but instead speciﬁcally affects the autophagoso-
mal system.
Mitophagy and xenophagy are blocked in IAP antagonist-
treated cells
One consequence defective autophagy is the accumu-
lation of mitochondria due to failure loss of mitophagy.
We examined the amount of mitochondria in MEFs
treated with LCL161 or thapsigargin by staining with
Mitotracker Green (MG). High dose (5 µM) LCL161 and
thapsigargin treated cells showed a clear increase in MG
signal, while low doses (0.5 μM) showed no signiﬁcant
increase (Fig. 8a, b). Birinapant also showed an increase in
mitochondrial mass only at the high doses that fully block
fusion (Fig. 8a, b). To conﬁrm that mitophagy is impaired
we turned to HeLa cells overexpressing Parkin as a well-
established model for inducing mitophagy. HeLa cells do
not express endogenous Parkin, a ubiquitin ligase that
ubiquitylates damaged mitochondria and induces their
clearance by mitophagy34. We treated HeLa cells without
Parkin and cells overexpressing mCherry-Parkin with
Oligomycin and Antimycin A to induce mitochondrial
damage either with or without LCL161 or birinapant for
16 h and examined the levels of cytochrome C as a marker
of mitochondria. There was a decrease in cytochrome C
levels with the oligomycin and Antimycin A treatment
only in the Parkin over-expressing cells (Fig. 8c). Addition
of LCL161 restored the levels of cytochrome C to some
extent, however not completely (Fig. 8c). MEFs were also
induced to over-express Parkin and treated in the same
way, but in our hands with all mitochondrial proteins
tested we also saw degradation in ATG5−/− MEFs and
also in non-Parkin over-expressing cells (data not shown),
suggesting that the degradation is not mitophagy in the
MEFs. Similar results have been published previously
indicating that there are few reliable markers for mito-
phagy in MEFs35. Therefor, not only is mitophagy inhib-
ited in IAP antagonist treated cells, but IAP antagonism
also blocks or at least slows the degradation of mito-
chondria by mitophagy in human cells too.
Xenophagy, which is conceptually similar to mitophagy
as it involves the tagging of intracellular bacteria with
ubiquitin followed by engulfment by autophagosomes and
degradation, is an early step in the recognition of a
number of pathogenic bacteria. Salmonella have been
used extensively as a model to study xenophagy and there
is signiﬁcantly more bacterial survival in autophagy deﬁ-
cient cells36. A block in mitophagy suggests loss of XIAP
could also lead to a deﬁciency in xenophagy. To test this,
XIAP was knocked out in MEFs using CRISPR-Cas9. Cells
infected under these conditions were ﬁxed and stained
using an antibody against S. Typhimurium LPS and the
number of bacteria in each cell counted, revealing more
salmonella in the XIAP CRISPR cells than in the wild type
(Fig. 8d). This was then conﬁrmed by lysing cells and
calculating the colony forming units (CFU) (Fig. 8e). Most
studies analysing xenophagy have used treatments or
mutants that block the early stages of autophagosome
formation. To the best of our knowledge little is known
about the effect of blocking fusion of autophagosomes
with lysosomes on xenophagy. As a model for blockage of
the fusion of autophagosomes with lysosomes, cells were
also treated with thapsigargin. Following 5 h of infection,
there is consistently more surviving bacteria in ATG5−/−
cells than in wild type as previously reported. Thapsi-
gargin treatment also resulted in accumulation of viable S.
Typhimurium, as did knockout of XIAP in the XIAP-
CRISPR cells (Fig. 8e). Both thapsigargin and XIAP deﬁ-
ciency result in increased S. Typhimurium survival to a
similar extent to Atg5 deﬁciency, supporting that
Autophagy inhibition is involved in all conditions.
Discussion
While we have demonstrated that cIAP2 and XIAP
promote autophagosome-lysosome fusion, the
Fig. 6 IAP antagonism blocks turnover of long lived proteins.
Wild type or Atg5−/− MEFs were labelled overnight with AHA as
described in methods. Cells were starved in HBSS or treated with HBSS
and LCL161 (0.5 μM), birinapant (0.5 μM) or thapsigargin (3 μM) for
three hours. Click it chemistry was used to label proteins and the
geometric mean ﬂuorescence intensity was measured for each
condition. Shown are the means of at least three independent
experiments and error bars show SEM
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mechanism is still not clear. Ubiquitylation regulates
many steps in vesicle trafﬁcking37 and it is likely that
cIAP2 and XIAP are regulating speciﬁc components of
the autophagosome–lysosome fusion machinery via their
ubiquitin ligase activity. The observation that endocytosis
is also not affected by IAP inhibition suggests ubiquity-
lation of some target on the autophagosomes themselves
is likely, however we cannot at this stage rule out that
some other function such as scaffolding may also be
playing a role.
One interesting aspect of these results is that we have
identiﬁed cIAP2 and XIAP as playing redundant roles in
regulating autophagy in MEFs. XIAP depletion alone in
humans leads to disease but XIAP−/− mice are in most
aspects normal, although they can be induced to develop
disease similar to XLP-2 in humans by infection with a
herpes virus, MHV-6838. One might expect that if there
was an absolute requirement for XIAP or cIAP2 in
autophagy that mice deﬁcient for either alone would
present with phenotypes associated with defects in
Fig. 7 IAP antagonism does not block endocytosis. a Wild type MEFs were grown overnight in 0.5% serum. Cells were either left untreated as a
control or treated with LCL161 (0.5 μM), birinapant (0.5 μM) for 4 h, or concanamycin A (2 nM) for 1 h before treatment with 100 ng/ml EGF in the
presence of 10 μg/ml cycloheximide for 0, 1 or 2 h. Cells were lysed and levels of EGFR were analysed by western blot. bWild type MEFs were treated
with LCL161 (0.5 μM) or not for 4 h. Alexaﬂuor 647-dextran (100 μg/mL) was added for 30 mins and then cells were washed and grown in normal
media for a further 2 h. The ﬁnal 30 min cells were stained with lysotracker (100 nM). Cells were ﬁxed and analysed on the ﬂuorescence microscope.
Shown are representative images and line proﬁle of lysotracker and dextran Alexaﬂuor 647. Experiments were performed at least 3 times. Pearsons
correlation coefﬁcients are shown in the right panel. Error bars represent the SEM from at least three experiments
Gradzka et al. Cell Death and Disease  (2018) 9:529 Page 10 of 15
Ofﬁcial journal of the Cell Death Differentiation Association
Fig. 8 IAP antagonism blocks mitophagy and xenophagy. Wild type MEFs were treated overnight with the indicated concentrations of LCL161,
birinapant or thapsigargin. Cells were stained with mitotracker green for 30 min and ﬂuorescence intensity quantiﬁed using ﬂow cytometry. a
representative histograms showing increases in mitotracker signal in IAP antagonist treated cells. b quantiﬁcation of mitotracker staining. Shown are
the means of the geometric mean ﬂuorescence intensity. Error bars are SEM from at least 3 independent experiments. P values were calculated using
t tests in Prism software. c IAP antagonism can block mitophagy. Wild type HeLa cells or HeLa cells expressing mCherry-Parkin were treated with
either LCL161 (5 µM), birinapant (50 µM) or oligomycin (1 µM) and Antimycin A (1 µM) (O/A) alone or in combination as indicated. LCL161 or
birinapant were added 4 h prior to Oligomycin and Antimycin A. Cells were incubated for 16 h before cells were harvested and lysates run on SDS-
PAGE and levels of cytochrome C and β-Actin analysed by western. d Immunoﬂuoresence and quantiﬁcation of Salmonella Typhimurium infection in
wild type and XIAP CRISPR MEFs. MEFs of the indicated genotypes were infected as described in methods, ﬁxed and stained for Salmonella
Typhimurium LPS. Shown are representative images. The mean number of Salmonella Typhimurium /cell is shown from two experiments. e
Xenophagy of Salmonella Typhimurium is impaired in XIAP deﬁcient cells. Wild type, Atg5−/− and XIAP−/−-CRISPR cells were infected with
Salmonella Typhimurium and incubated for 5 h. CFU/mL of internalised bacteria was then calculated. Thapsigargin was used where indicted to block
autophagosome–lysosome fusion by treating with 3 µM thapsigargin for 1 h before and then throughout the infection protocol. Error bars are SEM
from at least 3 independent experiments. P values were calculated using T tests in Prism software
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autophagy, but loss of both seems to be required before
spontaneous inﬂammation is seen2. This may be partly
explained by the overlapping functions seen for cIAP2
and XIAP in this study and may explain why XIAP deﬁ-
cient mice do not develop disease like humans do.
Relatively little is known about the substrates of XIAP,
however ubiquitylation of RIPK2 at NOD2 receptors was
shown to be required for NOD2 activation of NF-κB13.
Loss of NF-κB signalling results in a failure to up-
regulate cytokines in response to NOD2 signalling and
this link to NOD2 signalling is thought to be the cause of
Crohn’s disease in XIAP deﬁcient patients. While this
molecular connection between NOD2 and XIAP may
contribute to disease progression, NOD2 mutation does
not lead to the multiple other conditions that XIAP
deﬁciency causes39, suggesting that the story is not so
simple. There are numerous genes that are involved in
autophagy, including ATG16L1, NDP52, IRGM, and
LRRK2 that have been found to be mutated in Crohn’s
Disease patients; a number of these mutations also
manifest with multiple clinical presentations. Recently,
Niemann–Pick disease type C (NPC), a lysosomal sto-
rage disorder in which the NPC1 gene coding for a
lysosomal protein involved in lipid transport is mutated,
was also linked to early onset Crohn’s disease. Loss of
NPC1 function was also shown to be linked to defective
autophagy resulting in increased survival of intracellular
Salmonella and adherent-invasive E. coli40. Importantly,
this study showed that NOD2 induced NF-κB signalling
is normal in NPC1 mutated cells and enforced autophagy
induction could bypass the xenophagy defect and reduce
intracellular bacterial survival. Similarly impaired xeno-
phagy has also been seen in macrophages from patients
with NOD2 and XIAP mutations. We observed defects in
xenophagy of S. Typhimurium in XIAP deﬁcient ﬁbro-
blasts. Such defects in xenophagy may also contribute to
accumulation of invasive bacteria in XIAP deﬁcient
humans, again increasing the burden of bacteria that
needs to be dealt with by the immune system and
resulting in overactive inﬂammation. Additionally we
observed an accumulation of mitochondria in cells
treated with IAP antagonists at doses high enough to
block XIAP, as well as cIAP1 and cIAP2, suggesting that
the loss of IAPs also causes defects in mitophagy.
Mitophagy is important for clearing old or damaged
mitochondria and defects in mitophagy have been linked
to excessive ROS production and excessive inﬂamma-
some activation41. Mitophagy is in many ways mechan-
istically analogous to xenophagy and defects therein may
also contribute to inﬂammation in XIAP deﬁcient
patients. This suggests that the driving mechanism
behind multiple genetic mutations causing Crohn’s
Disease may be a loss of autophagy, and supports a role
for XIAP in regulating this process.
Many questions remain including dissection of the
mechanism behind cIAP2 and XIAPs regulation of
autophagosome–lysosome fusion, as well as the degree to
which autophagy defects contribute to inﬂammation
induced by IAP loss. It will be interesting to see if IAPs or
their substrates are also involved in other autophagy
related diseases such as protein misfolding diseases and or
lysosomal storage disorders.
Methods
Reagents
LCL161 and birinapant were purchased from ApexBio.
The following antibodies were used; EGFR (PA1-1110—
Thermo ﬁsher), XIAP (MAB822—R&D Systems), cIAP1
(was a kind gift from John Silke—WEHI Melbourne
Australia), LC3b (nb100–2220—Novus), LAMP2
(ab13524—Abcam). EGF was purchased from Biolegend
(catalogue No. 713108). Alexaﬂuor 647 Dextran
MW10,000 (catalogue No. D-22914), Lysotracker Red
DND-99 (catalogue No. L7528) and Mitotracker Green
(catalogue No. M7514) were purchased from Thermo
Fisher Scientiﬁc. Concanamycin A (catalogue No. Cay-
11050-25) was purchased from Cayman Chemical.
Cell culture
All cells were grown in DMEM High glucose (Gibco)
with 10% FCS and 1% Pen/Strep in 5% CO2 at 37 °C
unless otherwise stated.
Fluorescence microscopy of LC3
MEFs of the indicated genotypes were infected with
pBABE-puro-mCherry-EGFP-LC3B (pBABE-puro-
mCherry-EGFP-LC3B was a gift from Jayanta Debnath
(Addgene plasmid # 22418)). Cells were selected in Pur-
omycin 4 μg/ml. The selected cells were seeded at 50,000
cells/well of an 8 chamber μ-slide (Ibidi) and allowed to
plate down overnight. Cells were typically treated for 6 h
with the indicated concentrations of LCL161, birinapant
or thapsigargin (3 μM). Cells were treated for 30 min with
Hoechst to stain nuclei. Cells were imaged with a Keyence
BZ9000 ﬂuorescence microscope taking Z-stacks to and
using the “full focus” function in the analysis software to
make a single layer image from full focused features in
each layer of the Z-stack. These images were used to
count the number of GFP+ and mCherry+ puncta per
cell in image J using the analyse particles function to
count nuclei and ﬁnd maxima function to count puncta.
The ratio of mCherry+ /GFP+ puncta/cell was calcu-
lated from these measurements.
For Immunoﬂuorescence of LC3 and LAMP2, Wild
type MEFs were seeded in 8 well µ-slides (Ibidi) at 50,000
cells/well and incubated overnight. Cells were treated
with IAP antagonists as indicated and cells were washed
twice in warm PBS. Cell were ﬁxed in 4% PFA in PBS for
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10min followed by washing three times in PBS. Cells were
subsequently permeabilized in PBS with 50 µg/ml Digi-
tonin for 5 min followed by washing three times in PBS
then blocking with 3% BSA in PBS for 30min. Antibodies
against LC3 and Lamp2 were added 1:200 for 1 h in BSA
3% in a humidiﬁed chamber at 37 C. Cells were washed
three times in PBS followed by incubating with appro-
priate secondary antibodies at 1:500 in PBS 3% BSA for 1
h followed by washing 5 times in PBS. Images were taken
using a Zeiss LSM 880 with an Airyscan confocal
microscope at a 63 ×magniﬁcation (oil immersion) and
analysed with Zen (Zeiss) software.
siRNA treatment
MEFs were seeded at 150,000 cells/well of a 6 well plate.
The next day cells were washed with PBS and media
without antibiotics was added. Cells were transfected with
siRNA’s complexed with Lipofectamine RNAiMAX
according to manufacturers instructions. Brieﬂy, 7.5 µL of
20 µM stock stealth siRNA oligo was added to 150 µL of
optimem. Nine microlitre of RNAiMAX was added to
another 150 µL of optimum. The tubes were mixed
together before incubating at room temperature for 5 min.
250 µL of this was then added to the cells and incubated
overnight. Cells were seeded at 50,000 cells/well of an 8
chamber μ-slide (Ibidi) and allowed to plate down over-
night before microscopy was performed as described
above. The following stealth siRNAs were used from
Thermo Fisher Scientiﬁc; cIAP1 (MSS273215), cIAP2
(MSS202113) and XIAP (MSS202115). Activity of each
siRNA was conﬁrmed using qPCR with SYBR Select
Master Mix (applied biosystems # 4472908) and the fol-
lowing primers: cIAP1 (Forward 5′-GAAGAAAATGC
TGACCCTACAGA-3′, Reverse 5′-CATGACGACATC
TTCCGA-3′), cIAP2 (Forward 5′- TCGATGCAGAA
GACGAGA-3′ Reverse 5′-TTTGTTCTTCCGGATTAG
TGC-3′, XIAP (Forward 5′-GCTTGCAAGAGCTGGA
TTTT-3′, Reverse 5′-TGGCTTCCAATCCGTGAG-3′).
Actin was used as a reference gene. PCR was done in 384
well plates in a 7900HT Fast Real-Time PCR System.
Long-lived protein degradation assay
Cells were grown to ~70–80% conﬂuency in a 6-well
plate then washed with warm PBS and cultured in L-
methionine-free DMEM (cat. no. 21013-024, Gibco) for
30–60 min to deplete the intracellular methionine
reserves. Following methionine depletion, the cells were
labelled with 25 μM AHA in 10% dialysed FBS DMEM
(methionine-free) for 18 h. Dialysed FBS was made by
dialyzing against PBS with Slide-A-Lyzer mini dialysis
devices 3.5 k MWCO (Pierce—cat. No. 88403) overnight.
After labelling, the cells were washed with PBS and cul-
tured in regular DMEM containing 10 × L-methionine (2
mM) for 2 h to chase out short-lived proteins. LCL161
(0.5 μM), thapsigargin (3 μM), or birinapant (0.5 μM) were
added at this stage. Cells were washed in PBS and then
cultured for a further 3 h either in full media or HBSS
containing the indicated drugs. Cells were washed 2× in
PBS and then harvested and ﬁxed in 4% formaldehyde in
PBS for 15min at room temperature. After ﬁxation, the
cells are washed twice with 3% BSA in PBS. Cells were
permeabilized with 0.5% Triton X-100 in PBS for 20 min
at room temperature. Cells were resuspended in PBS and
store at 4 °C for detection of the corresponding alkyne-
tagged detection molecule.
Cells from the last step above were washed with 3% BSA
in PBS. 100 μL Click-iT® reaction cocktail was added to
each sample. Cells were incubated for 30min at room
temperature in the dark. Cells were washed once with 3%
BSA in PBS before being analysed using ﬂow cytometry.
EGFR degradation assay
A total of 500,000 cells/well were seeded in the morning
and let to plate down. In the evening, media was
exchanged for DMEM 0.5% FCS and cells incubated
overnight. The next day, cells were pre-treated for 4 h with
IAP antagonists birinapant (0.5 μM) or LCL161 (0.5 μM)
or for 1 h with concanamycin A (2 nM). Media was then
exchanged with serum free media alone or containing the
drugs. Cells were treated with EGF (100 ng/ml) and
cycloheximide (10 μg/ml) for 0, 1 or 2 h. Cells were lysed
on ice in RIPA buffer and 50 µg/ml protein per lane was
run on 10% SDS-PAGE before transferring to nitrocellu-
lose membranes and western blotting for EGFR
Assay of endocytosis and fusion with lysosomes
30,000 cells/well were seeded in 8 well microscope
culture slides (Ibidi) in 300–500 µL media. The next day
cells were treated with DMSO, LCL161 0.5 μM or bir-
inapant (0.5 μM) for 6 h. 2.5 h before end of drug treat-
ments, Dextran Alexaﬂuor 647 was added to a ﬁnal of
concentration of 100 µg/ml. Cells were incubated for 30
min at 37 °C. Cells were washed 2× in warm PBS. Fresh
media containing LCL161 or birinapant was added and
cells were incubated for a further 2 h. Lysotracker Red
(100 nM) was added for the ﬁnal 30 min. Cells were
washed 2× in warm PBS before ﬁxation in 4% paraf-
ormaldehyde (PFA) for 20min at room temperature. Cells
were washed 2× in PBS and stored at 4 °C until images
were taken on a Keyence BZ9000 ﬂuorescence micro-
scope. Hoechst was added 30min prior to imaging.
Pearsons correlation coefﬁcients were calculated using the
FIJI distribution of ImageJ and the Coloc2 plugin.
Electron microscopy
MEFs were cultured on glass cover slips and ﬁxed for
20min in 4% PFA plus 1% glutaraldehyde (Roth, Ger-
many) in PBS. After contrastation in 0.5%
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Osmiumtetroxide (30 min at RT) cells were dehydrated
and embedded in epoxy resin (Durcupan, Sigma-Aldrich,
Gillingham, UK). Images were taken using a Philips CM
100 transmission electron microscope.
Mitophagy assays
For mitotracker Green staining, Wild type MEFs were
treated overnight with the indicated concentrations of
LCL161, birinapant or thapsigargin. Cells were incubated
with 100 nM mitotracker Green for 30min in complete
media then washed in PBS and trypsinized then analysed
for ﬂuorescence intensity using ﬂow cytometry on a FACS
Calibur then analysed using FlowJo software.
For analysis of Parkin dependent mitophagy, HeLa cells
were infected with a lentivirus (pXLG3) expressing
mCherry-Parkin (human)42 or left uninfected. These
HeLas were then seeded at 4 × 105 for wild type and 6 × 105
cells/well in 6 well plates, left overnight and then incubated
for 4 h with 5 µM LCL161 or 50 µM birinapant followed by
addition of Oligomycin (1 µM) (Sigma Aldrich—O4876)
and Antimycin A (1 µM) (Sigma Aldrich—A8674) for 16 h.
Cells were harvested and lysed in DISC lysis buffer fol-
lowed by detection of Cytochrome C by western blot. Actin
was used as a loading control.
Xenophagy assays
S. Typhimurium used in all analysis was a patient
derived strain identiﬁed through sera agglutination.
Salmonella were cultured overnight in LB at 37 °C. On
the same day 100,000 cells/well of MEFs were seeded in
12 well plates. The next day, Salmonella were diluted
1:33 and incubate without shaking for 3 h at 37 °C. Sal-
monella were harvested by centrifugation and washed
with PBS two times before re-suspending in DMEM
without any antibiotics. The cells were adjusted to have
an OD600 of 0.5 by diluting with DMEM. One hundred
microlitre of Salmonella culture was added to each well
of MEFs and plates spun for 5 min in 37 °C centrifuge at
1800RPM. Cells were incubated for a further 5 min at 37
°C before washing cells twice with PBS at 37 °C. incubate
cells at 37 °C in DMEM without antibiotics for 20 min.
Cells were incubated in DMEM with gentamicin at 50
μg/ml for 40 min at 37 °C. Cells were changed to DMEM
containing 5 μg/ml gentamicin and incubated for 5 h at
37 °C. For CFU calculations cells were washed twice with
PBS and then lysed in 1 mL of lysis buffer (1% (v/v) TX-
100, 0.1% (w/v) SDS in PBS). Serial dilutions were plated
onto LB agar plates and CFU/mL calculated. For
immunoﬂuoresence infections were perfomed as above
but on either glass coverslips or in 8 chamber micro-
slides (Ibidi) and were also washed twice in PBS and
ﬁxed in 100% MeOH (−20 °C) for 20 min at (−20 °C).
Cells were stained with an antibody against S. Typhi-
murium LPS (santacruz sc52223) (1:100) in PBS with 3%
BSA for 30 min followed by staining with anti mouse
IgG-Cy3 (1:500) in PBS 3% BSA. Nuceli were stained
with Hoechst. Cells were imaged and the number of
bacteria per cell was counted from at least 50 cells for
each genotype per experiment.
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